Protocol

NAD+ IV infusion

NAD+ drip · intravenous nicotinamide adenine dinucleotide · NAD IV therapy · IV NAD+

The evidence base does not support the healthspan claims made for it. There is no human randomised controlled trial showing any longevity, healthspan or biological-ageing outcome from IV NAD+. The most relevant retrieved human data is a retrospective real-world pilot (PMC12907335) comparing IV NAD+ with IV nicotinamide riboside: it enrolled only 6 NAD+ recipients versus 8 NR recipients, was uncontrolled and unblinded, and was authored by staff of the commercial clinic delivering the treatment. It assessed tolerability and 30-day safety only, explicitly not efficacy. Notably, its findings cut against the marketing: the NAD+ arm reported moderate to severe abdominal cramping, diarrhoea, nausea, vomiting and chest pressure, while NR caused only minor tingling, and NAD+ infusions took 97 minutes versus 37. Metabolic readouts were exploratory only, and the authors could not even detect NAD+ concentration changes. The rationale for the intervention therefore rests on mechanism and on rodent work, not on demonstrated human outcomes. A candid signal: Artisan Regenerative's own service page describes NAD+ IV as "an unrecognized medical drug" and concedes limited clinical trial data, while simultaneously listing benefit claims spanning cognition, immunity, cardiovascular, liver, kidney and muscle function. REGULATORY, IMPORTANT LIMITATION: neither market's status was verified and both are returned as null rather than guessed. The TGA website timed out on four separate fetch attempts, so a safety alert that search results indicate exists at tga.gov.au titled "NAD, NAD+, NADH or NMN medicines sold in Australia" could not be opened or quoted; it is the single highest-priority follow-up and should be retrieved before any regulatory claim is published. No HSA source was successfully opened either. Search-result summaries suggested that NAD/NAD+/NADH are not permitted ingredients in Australian listed medicines and that Singapore restricts IV therapy outside licensed healthcare institutions, but both are secondhand search-engine paraphrases of non-authoritative pages and are deliberately excluded here. CLINICS: only Artisan Regenerative Centre is confirmed from its own site. Australian Longevity Clinic's homepage returned no service detail on fetch, so it is not listed despite the discovery note. Biogenix Australia was confirmed offering "NAD+ Therapy" from its own site but is not on the supplied AU clinic list, so it is excluded from offeredBy while still evidencing genuine AU availability.

At a glance

Evidence
Commercial
Singapore (HSA)
No HSA position on file
Australia (TGA)
No TGA position on file
Offered at
1 clinic

Singapore

Health Sciences Authority

HSA status
No position on file
In our SG set
Tracked in Singapore
SG clinics
1

Australia

Therapeutic Goods Administration

TGA status
No position on file
In our AU set
Tracked in Australia
AU clinics
None on file
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.

What it is

Plain-language explainer

NAD+ IV infusion delivers nicotinamide adenine dinucleotide, a coenzyme central to cellular energy metabolism and DNA repair, directly into the bloodstream over one to two hours. Clinics market it on the premise that NAD+ declines with age and that restoring it intravenously bypasses poor oral bioavailability. Advertised benefits typically span energy, cognition, sleep, skin quality and general "cellular" rejuvenation.

Categories

Protocol

Offered by

Where variis has verified this protocol (1)

Keep reading

Related coverage from the newsroom.

Suggest an updateJoin the community

Every entity profile on variis is sourced. Not medical advice.